Our partnerships
Cancer Research Horizons partners across the fields of academia, industry, drug discovery and investors.
The Patent covers technology relating to a novel target that enhances the oral bioavailability of certain cytotoxic oncology drugs, including topotecan. The terms of the Agreement remain confidential.
The Patent was initially filed by the NCI and is based upon the work of Professor Jan Schellens and Dr Alfred Schinkel. They showed that inhibition of a transporter protein from the family of transporters containing known multi-drug resistance proteins, could also be targeted to enhance the uptake of oncology drugs such as topotecan when orally administered.
Cancer Research Technology stated that it was happy to act as a conduit for the development of this important finding and hopes the Patent’s technology will eventually bring benefit to cancer patients worldwide. CRT initially undertook to cover the costs of the patent prosecution while the technology was being developed and CRT looked for a suitable commercial licensee.
